国产雷帕霉素药物洗脱支架治疗冠心病疗效评价

Efficacy of Partner Stent in Patient with Coronary Heart Disease

目的评价国产雷帕霉素药物洗脱支架(Partner)应用于冠心病的临床疗效及再狭窄情况。方法选择我院2006年2月-2007年10月期间接受Partner支架治疗的268例冠心病患者,其中急性心肌梗死136例,不稳定型心绞痛132例。观察Partner支架植入的手术成功率、术中并发症、住院期间及6个月随访期间的心血管事件和再狭窄发生率。结果支架植入成功率99.2%,术中和住院期间死亡2例,术后出现亚急性血栓1例,住院期间主要心脏不良事件发生率为1.1%。216例患者随访6个月,主要心脏不良事件发生率2.3%,56例冠状动脉造影复查的再狭窄率为5.4%,靶病变重建率为5.4%。结论应用Partner支架治疗冠心病是安全和有效的,主要心脏不良事件发生率低,支架内再狭窄率和靶病变重建率明显低于普通金属支架。

Objective To observe the effects and security of Partner stent （ homemade sirolimus -eluting stent） in patients with coronary heart disease （CHD）. Methods Total 268 patients with CHD treated with 481 Partner stents. Among the 268 patients, 136 were with acute myocardial infarction （AMI） and 132 were with unstable angina. The immediate angiographic outcome, complication in the procedure, six- months＇follow-up results, including main adverse cardiac events （MACE） and angiographic results, were assessed. Results A successful stenting procedure was achieved in 99.2% patients. Sub -acute instent thrombosis occurred in 1 patient, 2 patients died during operation and hospitalization. The MACEs rate was 1.1% during hospitalization and 2. 3% during 6 months＇ follow-up. At 6 months, angiographic results showed that instent restenosis rate （ISR） was 5.4%. The target vessel revascularization rate was 5.4%. Conclusion Partner stent implantation in patients with CHD is safe and effective, the ISR rate and TLR rate are significantly lower than those of bare metal stents.